Benitec Biopharma Inc (BNTC): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Benitec Biopharma Inc (BNTC) following the 2026 Q1 hedge fund 13F filings?

As of today, BNTC has moved +12.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +8.2%. Since the quarter end (March 31, 2026), BNTC gained +20.9% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Benitec Biopharma Inc (BNTC)

85 + Investors. Track Smart Money conviction in BNTC. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — BNTC

Based on 85 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added BNTC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

85 hedge funds hold BNTC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +130% more funds vs a year ago

fund count last 6Q

+48 new funds entered over the past year (+130% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 71% buying

58 buying24 selling

Last quarter: 58 funds were net buyers (25 opened a brand new position + 33 added to an existing one). Only 24 were sellers (13 trimmed + 11 sold completely). A clear majority buying is a strong confirmation signal.

➡️

Steady new buyers — ~25 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 24 → 6 → 21 → 25. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔄

Mostly new holders — 40% entered in last year

■ 22% conviction (2yr+) ■ 38% medium ■ 40% new

Only 19 funds (22%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💎

Buying through price weakness — shares +2%, value -19%

Value

-19%

+2%

Last quarter: funds added +2% more shares while total portfolio value only changed -19%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

🚀

Acceleration phase — new buyers rushing in

10 → 24 → 6 → 21 → 25 new funds/Q

New funds entering each quarter: 24 → 6 → 21 → 25. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

📊

Mixed cohorts — 33% veterans, 54% new entrants

■ 33% veterans ■ 13% 1-2yr ■ 54% new

Of 85 current holders: 28 (33%) held 2+ years, 11 held 1–2 years, 46 (54%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 25% AUM from major funds

25% from top-100 AUM funds

29 of 85 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

5.2

out of 10

Moderate Exit Risk

Exit risk score 5.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	85	71	19.72%
13F Shares	32M	32M	2.25%
Total Value	$345M	$427M	-19.15%
New Positions	25	21	+4
Increased Positions	33	29	+4
Closed Positions	11	4	+7
Reduced Positions	13	13	-
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

19.72%

13F Shares

32M

2.25%

Total Value

$345M

$427M

-19.15%

New Positions

Increased Positions

Closed Positions

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q1)

85 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BNTC. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 BNTC holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Lion Point Capital, LP	3.95%	62,000	$660K
2	Suvretta Capital Management, LLC	3.14%	11,548,351	$123.0M
3	Infinitum Asset Management, LLC	1.23%	923,006	$9.8M
4	Silverarc Capital Management, LLC	0.78%	717,725	$7.6M
5	Nantahala Capital Management, LLC	0.56%	1,438,371	$15.3M
6	MYDA Advisors LLC	0.39%	225,000	$2.4M
7	Empery Asset Management, LP	0.39%	30,440	$324K
8	AWM Investment Company, Inc.	0.22%	187,977	$2.0M
9	Ra Capital Management, L.P.	0.21%	1,850,000	$19.7M
10	Simplify Asset Management Inc.	0.09%	562,242	$6.0M
11	Burkehill Global Management, LP	0.08%	150,000	$1.6M
12	EntryPoint Capital, LLC	0.08%	24,322	$259K
13	Persistent Asset Partners Ltd	0.07%	18,307	$195K
14	Longaeva Partners L.P.	0.05%	125,000	$1.3M
15	Atom Investors LP	0.04%	52,463	$559K
16	Adage Capital Partners GP, L.L.C.	0.03%	2,120,672	$22.6M
17	Alyeska Investment Group, L.P.	0.02%	750,000	$8.0M
18	Janus Henderson Group plc	0.02%	2,876,380	$30.7M
19	Schonfeld Strategic Advisors LLC	0.01%	153,179	$1.6M
20	ADAR1 Capital Management, LLC	0.01%	17,500	$186K
21	Balyasny Asset Management L.P.	0.01%	653,835	$7.0M
22	Truvestments Capital LLC	0.01%	3,834	$41K
23	Cantor Fitzgerald, L. P.	0.01%	46,659	$497K
24	Franklin Resources Inc	0.01%	2,378,159	$25.3M
25	GAMMA Investing LLC	0.00%	6,705	$71K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Benitec Biopharma Inc (BNTC)

What does the Smart Money Trend signal show for BNTC?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added BNTC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BNTC?

More buyers than sellers — 71% buying: Last quarter: 58 funds were net buyers (25 opened a brand new position + 33 added to an existing one). Only 24 were sellers (13 trimmed + 11 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for BNTC holders?

Strong quality — 25% AUM from major funds: 29 of 85 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BNTC?

Mostly new holders — 40% entered in last year: Only 19 funds (22%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Benitec Biopharma Inc (BNTC) following the 2026 Q1 hedge fund 13F filings?

As of today, BNTC has moved +12.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +8.2%. Since the quarter end (March 31, 2026), BNTC has gained +20.9% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Benitec Biopharma Inc (BNTC)

Smart Money Signals — BNTC

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +130% more funds vs a year ago

More buyers than sellers — 71% buying

Steady new buyers — ~25 new funds per quarter

Mostly new holders — 40% entered in last year

Buying through price weakness — shares +2%, value -19%

Acceleration phase — new buyers rushing in

Mixed cohorts — 33% veterans, 54% new entrants

Strong quality — 25% AUM from major funds

Institutional Sentiment Summary — BNTC

Hedge Fund Ownership: BNTC

Market Analysis: BNTC

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: BNTC

Is It Too Late to Buy Benitec Biopharma Inc (BNTC) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: BNTC

Statistics: BNTC

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Benitec Biopharma Inc (BNTC)

Welcome to 13Foresight!